ストックスクリーナーアプリを入手
9.96
2.36%
0.23
前日終値:
$9.73
開ける：
$9.81
24時間の取引高:
69,235
Relative Volume:
0.12
時価総額：
$623.31M
収益：
当期純損益:
$-69.71M
株価収益率:
-8.3452
EPS:
-1.1935
ネットキャッシュフロー:
$-54.12M
1週間 パフォーマンス:
-13.32%
1か月 パフォーマンス:
-18.53%
6か月 パフォーマンス:
-21.88%
1年 パフォーマンス:
+48.44%
1日の値動き範囲:
$9.805
$10.05
1週間の範囲:
$9.475
$11.92
52週間の値動き範囲:
$5.28
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
名前
Design Therapeutics Inc
セクター
電話
858-293-4900
住所
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
9.96 | 623.31M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
509.06 | 129.03B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.68 | 95.29B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
798.07 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.67 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.30 | 42.00B | 5.76B | 514.49M | 1.10B | 4.4813 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-02 | 開始されました | Wells Fargo | Overweight |
| 2026-05-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-16 | 開始されました | Jefferies | Buy |
| 2026-01-07 | 開始されました | Oppenheimer | Outperform |
| 2025-12-03 | 開始されました | Craig Hallum | Buy |
| 2025-12-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-05-04 | アップグレード | Goldman | Sell → Neutral |
| 2022-06-10 | 開始されました | Wedbush | Outperform |
| 2022-05-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-19 | 開始されました | Goldman | Sell |
| 2021-04-20 | 開始されました | Goldman | Neutral |
| 2021-04-20 | 開始されました | Piper Sandler | Overweight |
| 2021-04-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Design Therapeutics Inc (DSGN) 最新ニュース
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 - Seeking Alpha
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance UK
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target - marketscreener.com
tm2619715-5_s1none30.1514628s - SEC.gov
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Australia
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Singapore
Solid Biosciences (Nasdaq:SLDB)Stock Analysis - Simply Wall Street
Seres Therapeutics (Nasdaq:MCRB)Stock Analysis - Simply Wall Street
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to S&P Biotechnology Select Industry Index - marketscreener.com
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com Australia
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com South Africa
Design Therapeutics at Cantor conference: biomarker push takes center stage - Investing.com
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com Canada
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com India
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com UK
DSGN: DT-216 achieved robust biomarker and clinical gains in FA, with pivotal data expected in Q1 2027 - TradingView
A biotech company's conference chat will be webcast live Sept. 9. - Stock Titan
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Risk Parity Rebalance - vinanet.vn
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Corrective Wave - careplusvn.com
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Wide Range Bar - dars.gov.et
Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - sahmcapital.com
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch - Yahoo Finance
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch - AOL.com
Design Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
DSGN Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesFiscal Year Earnings - vinanet.vn
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.06% Stock GainMid-Term Outlook - Vinanet
Design Therapeutics Stock Price Forecast. Should You Buy DSGN? - StockInvest.us
Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares - Stock Titan
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake - Stock Titan
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co. - MarketBeat
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - finance.yahoo.com
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplinePreliminary Results - vinanet.vn
Renaissance Technologies LLC Buys 121,100 Shares of Design Therapeutics, Inc. $DSGN - MarketBeat
Design Therapeutics (DSGN) Rises 1.47% as Gene Therapy Plays Draw AttentionRectangle Pattern - dars.gov.et
Design Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Design Therapeutics Q2 Net Loss Narrows - Moomoo
Design Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Design Therapeutics posts Q2 loss, updates clinical trials - Investing.com
Design Therapeutics Q2 Net Loss Narrows - marketscreener.com
Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - marketbeat.com
Design Therapeutics Q2 net loss narrower than expected - TradingView
Design Therapeutics reports $20.2M Q2 net loss, $207.4M cash as RESTORE-FA advances - TradingView
Design Therapeutics, Inc. 2Q 2026: Net loss $(20,165)K, EPS $(0.32) — 10-Q Summary - TradingView
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial - Moomoo
Design Therapeutics Inc (DSGN) 財務データ
収益
当期純利益
現金流量
EPS
Design Therapeutics Inc (DSGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Logos Global Master Fund LP | Director |
Nov 14 '25 |
Proposed Sale |
7.06 |
620,000 |
4,377,200 |
0 |
| Logos Global Master Fund LP | Director |
Nov 07 '25 |
Proposed Sale |
6.87 |
415,000 |
2,851,050 |
0 |
6.50%
大文字化:
|
ボリューム (24 時間):